secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K/A
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001193125-23-242481
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences reports final 2023 annual meeting results; say-on-pay fails
-----------------------------------------------------------------------------

- Two Class III directors elected: Eichenfield (16.4M for) and Wagner (16.8M for); McIntyre and Hacke not elected.
- Advisory vote on executive compensation failed: 9.9M for, 11.8M against, 5.8M abstain.
- Stockholders favored annual say-on-pay frequency (13.96M votes); Board to decide.
- Ratification of Mayer Hoffman McCann as auditor passed (17.3M for, 3.8M against).
- Amended equity plan approved; two shareholder proposals (bylaws, preferred stock rights) voted down.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523242481/0001193125-23-242481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312523242481/d531637d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-242481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer